Table 2.
List of adjusted variables in the three population-adjusted ITCs
| MAIC by Oluwole et al. (Adjusted 7 variables) |
MAIC by the authors (Adjusted 10 variables) |
CAR-T prediction model by the authors (Adjusted 13 variables) |
|---|---|---|
| Cell of origin (e.g., DLBCL/other types of LBCL) | Predominant histology (DLBCL + tFL vs. other) | Predominant histology (DLBCL + tFL vs. other) |
| IPI score (< 2 vs. ≥ 2) | IPI (< 3 vs. ≥ 3) | IPI (< 3 vs. ≥ 3) |
| ECOG (1 vs. 0) | ECOG (1 vs. 0) | ECOG (1 vs. 0) |
| Number of prior therapies (< 3, 3, or ≥ 4) | Prior lines of therapy (< 3 vs. ≥ 3) | Prior lines of therapy (< 3 vs. ≥ 3) |
| Relapsed/refractory disease (relapsed/refractory) | History of refractory disease (yes vs. no) | History of refractory (yes vs. no) |
| Double/triple hit (yes vs. no) | Double/triple hits (yes vs. no) | Double/triple hits (yes vs. no) |
| Disease stage (< 3, 3, or 4) |
Sex Prior ASCT (yes vs. no) Relapse ≤ 12 months post-ASCT (yes vs. no) Bulky disease (≥ 10 cm vs. < 10 cm) |
Sex Prior ASCT (yes vs. no) Relapse ≤ 12 months post-ASCT (yes vs. no) Bulky disease (≥ 10 cm vs. < 10 cm) Bridging chemotherapy (yes vs. no) Fludarabine-based LDC (yes vs. no) Bendamustine-based LDC (yes vs. no) |
Variables that were only able to be adjusted for in the prediction model are in bold type
ASCT autologous stem cell transplant, CAR-T chimeric antigen receptor T-cell therapy, DLBCL diffuse large B-cell lymphoma, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, ITC indirect treatment comparison, LBCL large B-cell lymphoma, LDC lymphodepleting chemotherapy, MAIC matching-adjusted indirect comparison, tFL transformed follicular lymphoma